WCM
SYRS

Wedge Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Wedge Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,333
Closed -$762K – 643
2019
Q1 		$762K Buy
8,333
+2,194
+36% +$153K 0.01% 401
2018
Q4 		$342K Hold
6,139
– – ﹤0.01% 476
2018
Q3 		$731K Buy
+6,139
New +$712K 0.01% 425

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wedge Capital Management's SYRS Position: Q2 2019 in Review

Wedge Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2019, closing a stake of 8,333 shares — an estimated $762K sold.

Wedge Capital Management first reported a position in SYRS in Q3 2018 and held it in 3 quarters. The position peaked at $762K in Q1 2019. 68 funds tracked by Wall St. Rank hold SYRS as of Q2 2019.

  • Wedge Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Wedge Capital Management sold 8,333 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $762K.
  • Wedge Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Wedge Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $762K in Q1 2019.
  • 68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Wedge Capital Management's 13F filing for Q2 2019, filed 1 Aug 2019.